Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer
NCT05707468Not yet recruiting
- Sponsor
- Changhai Hospital
- Start
- May 2024
- Primary completion
- Mar 2025
- Countries
- 1
01
Overview
Randomised, open-label trial in prostate cancer (PCa) (2 arms), sponsored by Changhai Hospital. Primary endpoint: Progression-Free Survival at 3 years. Planned start May 2024; status: not yet recruiting.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05707468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05707468.